NVAX Share Price

Open 1.54 Change Price %
High 1.64 1 Day -0.03 -2.07
Low 1.38 1 Week 0.25 21.37
Close 1.42 1 Month 0.29 25.66
Volume 25132151 1 Year -6.01 -80.89
52 Week High 8.49
52 Week Low 0.73
NVAX Important Levels
Resistance 2 1.66
Resistance 1 1.56
Pivot 1.48
Support 1 1.28
Support 2 1.18
NASDAQ USA Most Active Stocks
YHOO 52.58 0.00%
YHOO 52.58 0.00%
YHOO 52.58 0.00%
FNFG 10.18 -0.20%
DCTH 0.16 0.00%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
AEZS 2.34 129.41%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
More..
NASDAQ USA Top Gainers Stocks
AEZS 2.34 129.41%
SCHS 0.05 66.67%
LOCM 0.09 50.00%
MYRX 0.08 33.33%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
CPSL 0.11 22.22%
VRTX 159.69 20.83%
ENG 1.40 19.66%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
ZOOM 0.02 -80.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
CPWR 3.00 -52.00%
AMCF 0.01 -50.00%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
QKLS 0.11 -47.62%
More..

Novavax, Inc. (NASDAQ: NVAX)

NVAX Technical Analysis 2.5
As on 19th Jul 2017 NVAX Share Price closed @ 1.42 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 1.87 & Strong Buy for SHORT-TERM with Stoploss of 1.06 we also expect STOCK to react on Following IMPORTANT LEVELS.
NVAX Target for July
1st Target up-side 1.31
2nd Target up-side 1.43
3rd Target up-side 1.54
1st Target down-side 0.99
2nd Target down-side 0.87
3rd Target down-side 0.76
NVAX Other Details
Segment EQ
Market Capital 253984256.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.novavax.com
NVAX Address
NVAX
20 Firstfield Road
Gaithersburg, MD 20878
United States
Phone: 240-268-2000
NVAX Latest News
Interactive Technical Analysis Chart Novavax, Inc. ( NVAX NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Novavax, Inc.
NVAX Business Profile
Novavax, Inc. (Novavax) is a clinical stage biopharmaceutical company. The Company focuses on developing recombinant vaccines. The Company�s technology platform is based on recombinant vaccine technology that includes the virus-like particles (VLPs). The Company's vaccine candidates are genetically engineered three-dimensional nanostructures, which incorporate immunologically important recombinant proteins. In July 2013, Novavax acquired approximately 97.4% of shares in Isconova AB.